the publication�s purpose is to be a "force for good and a platform for much needed change and to generate critical debate"..
marketwatch: "new migraine drugs have promise -- and a ,500 price tag.".
may 17, 2018 -- the fda has approved the first in a new class of migraine drugs that aim to fight painful...